(OMER) Omeros - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 887m USD | Total Return: 255.9% in 12m
Avg Turnover: 16.2M
Qual. Beats: 1
Qual. Beats: 1
Warnings
Interest Coverage Ratio -3.0 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -12.29 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader, Pead, Confidence
Omeros Corporation (OMER) is a Seattle-based clinical-stage biopharmaceutical company focused on small-molecule and protein therapeutics. Its primary research targets immunologic diseases, inflammatory disorders, and orphan indications. The company’s lead candidate, narsoplimab, targets the lectin pathway by inhibiting MASP-2 and is currently being evaluated for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA).
The company operates within the biotechnology sector, where business models typically rely on heavy R&D investment and the acquisition of patents to secure market exclusivity for orphan drugs. Omeros maintains a diverse pipeline including OMS1029 for lectin pathway disorders and OMS527 for movement and compulsive disorders. Unlike commercial-stage firms, clinical-stage companies often face high volatility based on FDA regulatory milestones and clinical trial data releases.
Investors looking for deeper technical analysis and valuation metrics should consult ValueRay for further data. Beyond its lead programs, Omeros is engaged in preclinical research involving MASP-3 inhibitors for alternative pathway disorders and Targeted Complement Activating Therapy for multidrug-resistant organisms.
- FDA decision on Narsoplimab BLA resubmission for TA-TMA drives valuation
- Clinical trial data from Phase 2 OMS906 determines alternative pathway potential
- Royalty streams from Omidria sales provide essential non-dilutive operating capital
- High R&D expenditure necessitates additional capital raises or strategic partnerships
- Progress of MASP-3 small-molecule inhibitors defines long-term pipeline expansion value
| Net Income: 86.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.31 > 0.02 and ΔFCF/TA 96.59 > 1.0 |
| NWC/Revenue: 1.22k% < 20% (prev 3.15k%; Δ -1.92k% < -1%) |
| CFO/TA -0.33 > 3% & CFO -94.8m > Net Income 86.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.5m) vs 12m ago 9.39% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.80% > 50% (prev 0.18%; Δ 3.62% > 0%) |
| Interest Coverage Ratio: -2.98 > 6 (EBITDA TTM -104.3m / Interest Expense TTM 35.3m) |
| A: 0.42 (Total Current Assets 180.4m - Total Current Liabilities 59.4m) / Total Assets 286.2m |
| B: -3.00 (Retained Earnings -857.6m / Total Assets 286.2m) |
| C: -0.40 (EBIT TTM -105.2m / Avg Total Assets 260.7m) |
| D: -2.45 (Book Value of Equity -856.9m / Total Liabilities 349.5m) |
| Altman-Z'' = -12.29 = D |
| DSRI: 0.28 (Receivables 37.5m/5.63m, Revenue 9.89m/412k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.64 (AQ_t 0.33 / AQ_t-1 0.52) |
| SGI: 24.01 (Revenue 9.89m / 412k) |
| TATA: 0.63 (NI 86.2m - CFO -94.8m) / TA 286.2m) |
| Beneish M = 13.31 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 11.96 with a total of 1,082,170 shares traded.
Over the past week, the price has changed by -6.45%,
over one month by -14.29%,
over three months by +0.17% and
over the past year by +255.90%.
Omeros has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold OMER.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 33.5 | 180.1% |
P/E Forward = 11.4286
P/S = 89.6187
P/B = 8.4414
P/EG = 0.8053
Revenue TTM = 9.89m USD
EBIT TTM = -105.2m USD
EBITDA TTM = -104.3m USD
Long Term Debt = 208.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 26.3m USD (from shortTermDebt, last quarter)
Debt = 324.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.5m
Net Debt = 188.9m USD (calculated: Debt 324.2m - CCE 135.3m)
Enterprise Value = 1.08b USD (886.6m + Debt 324.2m - CCE 135.3m)
Interest Coverage Ratio = -2.98 (Ebit TTM -105.2m / Interest Expense TTM 35.3m)
EV/FCF = 12.27x (Enterprise Value 1.08b / FCF TTM 87.6m)
FCF Yield = 8.15% (FCF TTM 87.6m / Enterprise Value 1.08b)
FCF Margin = 885.9% (FCF TTM 87.6m / Revenue TTM 9.89m)
Net Margin = 871.0% (Net Income TTM 86.2m / Revenue TTM 9.89m)
Gross Margin = unknown ((Revenue TTM 9.89m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.76 (Enterprise Value 1.08b / Total Assets 286.2m)
Interest Expense / Debt = 10.90% (Interest Expense 35.3m / Debt 324.2m)
Taxrate = 0.11% (57.0k / 51.3m)
NOPAT = -105.1m (EBIT -105.2m * (1 - 0.11%)) [loss with tax shield]
Current Ratio = 2.78 (Total Current Assets 180.4m / Total Current Liabilities 64.8m)
Debt / Equity = -5.12 (negative equity) (Debt 324.2m / totalStockholderEquity, last quarter -63.3m)
Debt / EBITDA = -1.81 (negative EBITDA) (Net Debt 188.9m / EBITDA -104.3m)
Debt / FCF = 2.15 (Net Debt 188.9m / FCF TTM 87.6m)
Total Stockholder Equity = -158.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 33.06% (Net Income 86.2m / Total Assets 286.2m)
RoE = 12.32% (Net Income TTM 86.2m / Total Stockholder Equity 699.2m)
RoCE = -11.59% (EBIT -105.2m / Capital Employed (Equity 699.2m + L.T.Debt 208.5m))
RoIC = -44.02% (negative operating profit) (NOPAT -105.1m / Invested Capital 238.8m)
WACC = 10.47% (E(886.6m)/V(1.21b) * Re(10.32%) + D(324.2m)/V(1.21b) * Rd(10.90%) * (1-Tc(0.00)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 35.96 | Cagr: 1.71%
[DCF] Terminal Value 68.37% ; FCFF base≈87.6m ; Y1≈88.0m ; Y5≈93.2m
[DCF] Fair Price = 12.11 (EV 1.07b - Net Debt 188.9m = Equity 876.7m / Shares 72.4m; r=10.47% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.08 | Chg30d=+121.36% | Revisions=+20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.20 | Chg30d=+44.59% | Revisions=+20% | Analysts=3
EPS current Year (2026-12-31): EPS=0.42 | Chg30d=+127.49% | Revisions=+0% | GrowthEPS=-79.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=0.54 | Chg30d=-60.78% | Revisions=+14% | GrowthEPS=+27.6% | GrowthRev=+136.2%
[Analyst] Revisions Ratio: +20%